Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Patients with presumed non-obstructive BPH (Q max ≥ 15 ml/s) treated with tolterodine ER 4 mg/day for OAB symptoms, alone or added to unsuccessful alpha-blocker treatment of ≥6 weeks duration, were observed for 12 weeks in a non-interventional study to generate real-life efficacy and safety data. Patients completed the IPSS, the OAB-q and a 2-day micturition diary at baseline and 12 weeks. PVR was determined sonographically. Seven hundred and forty one patients were analysed. Mean PVR did not increase (25.4 ± 26.5 vs. 29.3 ± 30.9 ml at baseline). AUR requiring catheterization occurred in two patients, acute UTI in four patients. Median IPSS total scores decreased from 17 to 10, IPSS QoL scores from 4 to 2, OAB-q symptom bother scores from 50.0 to 22.5 and OAB-q HRQL scores increased from 59.2 to 81.6. In men with OAB symptoms and presumed non-obstructive BPH, tolterodine ER provided considerable symptomatic and QoL improvements with a low risk of AUR, acute UTI, or increased PVR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61:37–49

    Article  PubMed  Google Scholar 

  2. Abrams P, Cardozo L, Khoury S et al (2005) Incontinence. Management, vol 2. Health Publication Ltd, Plymouth

  3. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al (2003) Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169:2253–2256

    Article  PubMed  CAS  Google Scholar 

  4. Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557, discussion 1564

    Google Scholar 

  5. Cockett ATK AY, Chatelain C et al (1991) Recommendations of the International Consensus Committee. In: Cockett ATK AY, Chatelain C et al (eds) Proceedings of the international consultation on benign prostatic hyperplasia (BPH). Paris, pp 279–288

  6. Coyne K, Revicki D, Hunt T et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574

    Article  PubMed  CAS  Google Scholar 

  7. Coyne KS, Matza L, Kopp Z et al (2005) Determining the minimally important difference of the overactive bladder questionnaire (OAB-q). Value Health 8(6):A9

    Google Scholar 

  8. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174:2273–2275, discussion 2275–2276

    Google Scholar 

  9. Layton D, Pearce GL, Shakir SA (2001) Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 24:703–713

    Article  PubMed  CAS  Google Scholar 

  10. Lee JY, Kim HW, Lee SJ et al (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817–820

    Article  PubMed  CAS  Google Scholar 

  11. Lim E, Chia SJ (2005) Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? International Continence Society ICS, Montreal. http://www.continet.org/publications/2005/pdf/0205.pdf

  12. Madersbacher S, Alivizatos G, Nordling J et al (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46:547–554

    Article  PubMed  Google Scholar 

  13. McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398

    Article  PubMed  CAS  Google Scholar 

  14. Meigs JB, Barry MJ, Giovannucci E et al (1999) Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 162:376–382

    Article  PubMed  CAS  Google Scholar 

  15. Michel MC, de la Rosette JJ, Piro M et al (2004) Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J Urol 172:601–604

    Article  PubMed  CAS  Google Scholar 

  16. Michel MC, Mehlburger L, Bressel HU et al (1998) Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 160:784–791

    Article  PubMed  CAS  Google Scholar 

  17. Michel MC, Schneider T, Krege S et al (2002) Does gender or age affect the efficacy and safety of tolterodine? J Urol 168:1027–1031

    Article  PubMed  CAS  Google Scholar 

  18. Okada H, Shirakawa T, Muto S et al (2004) Propiverine hydrochloride relieves irritative symptoms of benign prostatic hyperplasia. J Urol 171 (Suppl):abstract 1358

    Google Scholar 

  19. Hartung J (1993) Statistik, Lehr- und Handbuch der angewandten Statistik. 9th edn. Oldenbourg, München Wien, p 204

  20. Rackley R, Weiss J, Rovner ES et al (2007) Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology (in press)

  21. Roehrborn CG, Bruskewitz R, Nickel JC et al (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171:1194–1198

    Article  PubMed  Google Scholar 

  22. Roehrborn CG, McConnell JD, Barry MJ et al (2003) AUA guideline on the management of benign prostatic hyperplasia. http://www.auanet.org/timssnet/products/guidelines/main_reports/bph_management/preface_toc.pdf

  23. Saito H, Yamada T, Oshima H et al (1999) A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin in the benign prostatic hypertrophy with pollakiuria and/or urinary incontinence. Jpn J Urol Surg 12:525–536

    Google Scholar 

  24. van Kerrebroeck P, Abrams P, Chaikin D et al (2002) The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:179–183

    Article  PubMed  Google Scholar 

  25. Verhamme KM, Dieleman JP, van Wijk MA et al (2005) Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 47:494–498

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are indebted to the 284 investigators who documented the patients in this trial.

Author information

Authors and Affiliations

  1. Urologische Klinik, Evangelisches Krankenhaus Oberhausen, Virchowstrasse 20, 46047, Oberhausen, Germany

    K. Höfner

  2. Pfizer Pharma GmbH, Karlsruhe, Germany

    M. Burkart & G. Jacob

  3. Klinik für Urologie, Medizinische Hochschule Hannover, Hannover, Germany

    U. Jonas

Authors
  1. K. Höfner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Burkart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Jonas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Höfner.

Additional information

Supported by Pfizer Pharma GmbH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Höfner, K., Burkart, M., Jacob, G. et al. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 25, 627–633 (2007). https://doi.org/10.1007/s00345-007-0212-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0212-5

Keywords

Search

Navigation